Molecular data
| Physical form | Lyophilized powder blend |
|---|---|
| Available sizes | 20mg |
How it works
Angiogenesis & Cytoprotection
BPC-157 upregulates VEGF expression and promotes new blood vessel formation, delivering nutrients and oxygen to damaged tissue. It also activates the NO system and demonstrates broad cytoprotective properties.
- VEGF-mediated angiogenesis
- Nitric oxide system modulation
- Gastric and tissue cytoprotection
Cell Migration & Actin Regulation
TB-500 sequesters G-actin monomers and promotes cytoskeletal remodeling, enabling repair cells to migrate to injury sites. It also activates integrin-linked kinase (ILK) for tissue repair signaling.
- Actin-mediated cell migration
- Integrin-linked kinase activation
- Anti-fibrotic remodeling
Complementary Repair Cascade
BPC-157 initiates vascular support (blood flow to injury), while TB-500 mobilizes repair cells to the site. Together they address two distinct phases of tissue repair — perfusion and cellular migration.
- Phase 1: Blood flow restoration (BPC-157)
- Phase 2: Cell mobilization (TB-500)
- Combined anti-inflammatory effects
What the research shows
Tendon & Ligament
BPC-157 accelerates tendon healing while TB-500 enhances cell migration to the injury site for coordinated soft tissue repair.
Chang et al. 2014
Wound Healing
TB-500 promotes dermal healing and reduces scarring; BPC-157 provides vascular support for nutrient delivery to wound sites.
Malinda et al. 2007
Vascular Repair
BPC-157 promotes angiogenesis via the NO system while TB-500 supports cardiac cell migration through ILK activation.
Sikiric et al. 2019
Inflammation Control
Both peptides demonstrate anti-inflammatory properties through distinct mechanisms, creating a more controlled healing environment.
Sikiric et al. 2011
Specification
| Components | BPC-157 + TB-500 (Thymosin Beta-4) |
|---|---|
| BPC-157 Sequence | 15 amino acids (Gly-Glu-Pro-Pro-Pro...) |
| TB-500 Fragment | 43-amino acid active region of Tβ4 |
| Form | Lyophilized powder blend |
| Purity | ≥99% per component (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage (lyophilized) | -20°C for long-term stability |
| Storage (reconstituted) | 2–8°C, use within 14-21 days |
| Solubility | Bacteriostatic water for reconstitution |
| COA | Included with every order |
| Strength | 20mg |
| Purity (HPLC) | >99% (HPLC) |
| Appearance | White to off-white powder |
| Stability | 24 months from manufacture date when stored properly |
Frequently asked questions
Why combine BPC-157 and TB-500?
BPC-157 and TB-500 target complementary repair mechanisms. BPC-157 promotes blood vessel formation (angiogenesis) to deliver nutrients to injured tissue, while TB-500 mobilizes repair cells through actin regulation. Together they address both vascular support and cellular migration phases of tissue repair.
Has this combination been studied in clinical trials?
No. The combination has not been studied as a single formulation in clinical trials. The synergy rationale is based on complementary mechanisms from individual component research (200+ BPC-157 studies, 170+ TB-500 studies). Both are well-studied individually in preclinical models.
Is this blend FDA approved?
No. Neither BPC-157 nor TB-500 is FDA approved for any indication. This blend is sold exclusively for in vitro laboratory research purposes and is not intended for human consumption.
How should this blend be stored?
Store lyophilized at -20°C for long-term stability. After reconstitution with bacteriostatic water, refrigerate at 2-8°C and use within 14-21 days. Both components maintain stability under standard peptide storage conditions.
What purity testing is performed?
Each component undergoes independent third-party testing including HPLC for purity verification, mass spectrometry for molecular weight confirmation, and endotoxin testing. A Certificate of Analysis is included with every order.
Literature
- PubMed Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
- PubMed Thymosin beta 4 activates integrin-linked kinase and promotes cardiac cell migration
- PubMed BPC 157 and NO system
- PubMed Thymosin beta-4 promotes dermal healing
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.